PTPRC and endometrial cancer: We validated CTC by IF×3 from a spectrum of blood from patients with different (Figure 2A) clinical status, Grade 1, Stage IA nonmetastatic endometrial cancers (pT1a pN0) (Figure 2(Ai)) and Grade 3, Stage IVB metastatic (pT3a N0 M1) (Figure 2(Aii)) in endometrial cancers, and (B) samples of origin, including biopsy sample from a liver lesion in metastatic squamous cell carcinoma (Figure 2(Bi)) and during surgical resection of Grade 1 (pT1b N0) tumor in lung cancers (Figure 2(Bii)) using the DAPI/CK-FITC/EpCAM-PE/CD45-Cy5 antibody cocktail.